PharmEnable Dual CDK inhibitor

PharmEnable's Dual CDKs program is a preclinical small molecule therapeutic being developed for the treatment of various cancers. The program focuses on the discovery and optimization of small molecules that simultaneously inhibit two specific cyclin-dependent kinases (CDKs), which are essential enzymes for cell cycle regulation and transcription. By employing a dual-targeting approach, PharmEnable aims to enhance anti-tumor activity and potentially mitigate the development of resistance often observed with monotherapeutic CDK inhibitors. The program is currently in the lead optimization phase and utilizes PharmEnable's proprietary AI-driven platform to design molecules with high selectivity and improved drug-like properties.

Other names

PharmEnable Dual CDK program